


Table 1
Evaluation of olefin tethers for the EYRCM



Entry	Tether	Solvent	Temp (°C)	Time	Yield ^a (%)
1		PhH	65	1.5 h	0
2		PhMe	110	1.5 h	0
3		PhMe	110	1.5 h	47
4		PhH	80	6 h	15 ^b
5		PhH	65	30 min	91
6		PhH	65	3 h	92

^a Isolated yields.

^b Isolated yield of free amide after TBS deprotection with TBAF.

the olefin is oriented in close proximity to the alkyne and is poised for the ensuing EYRCM with minimal interference by the Lewis basic carbonyl. In light of this, we also prepared the *t*-butyldimethylsilyl allylamide (Table 1, entry 4), which would enable access to a more hydrolytically labile cyclic carbonate by treatment with tetra-*n*-butylammonium fluoride (TBAF). However, the tandem EYRCM–TBAF treatment provided the desired product in only 15% yield, due to the lability of the silylcarbamate under the EYRCM conditions.


None of the carbonate- or carbamate-based tethers proved superior to silicon-based olefin tethers⁶ examined for this transformation. When the allylsilane tether, first reported by Grubbs and Yao,¹⁰ was subjected to the EYRCM conditions, the desired product **10** was afforded in 91% yield (Table 1, entry 5) within 30 min. Furthermore, the allyloxysilane tether (Table 1, entry 6)¹¹ also provided the desired enyne metathesis product in 92% yield, albeit requiring a longer reaction time. Interestingly, in related systems we observed that the diethylallyloxysilane tether (Table 1, entry 6) was optimal as compared to the corresponding dimethyl and diisopropyl variants. The diethylallyloxysilane tether provided the best balance between stability and reactivity. The dimethylallyloxysilane tether was too labile under the EYRCM reaction conditions leading to premature desilylation, while the diisopropylallyloxysilane was both more difficult to prepare due to lower rate of etherification and gave the desired metathesis products in low yields.

The two optimal silicon-based tethers for the key enyne metathesis (Table 1, entries 5 and 6) were utilized in the synthesis of the


bicyclic core structure of the illudins. In addition to our previously described enantioselective synthesis of (+)-aldehyde **8**,⁶ we also developed a simple, large-scale four-step synthesis of racemic aldehyde **8** from pentane-2,4-dione (**11**, Scheme 2) given the activity of both enantiomers of irofulven.^{5g} Sequential double alkylation,¹² mono olefination, and InBr₃-catalyzed trimethylsilylcyanation¹³ provided the versatile silyl cyanohydrin **14** in multi-gram quantities (Scheme 2). Reduction of the nitrile **14** with diisobutylaluminum hydride (DIBAL-H) readily provided the desired racemic aldehyde **8** in 69% yield on 2-gram scale. This facile synthesis allowed rapid access to multi-gram quantities of aldehyde **8** as the key precursor for the AB-ring system shared in illudins.⁶

Five readily available acetylides¹⁴ **15a–d** were added to aldehyde **8** as the corresponding lithium acetylides to provide diols **16a–d** (Scheme 3).⁶ The diastereoselectivity (ca. 6:1)¹⁵ of these reactions was consistent with a Felkin–Ahn mode of addition. The allylsilane tether was introduced on substrates **16a–c** through selective silylation of the secondary hydroxyl group to afford the dienynes **17a–c** in 68–83% yields.

With the allylsilane substrates **17a–c** in hand, we examined their respective EYRCM reactions for accessing the functional bicyclic core common to the illudins (Table 2). These optimization studies were monitored directly by ¹H NMR analysis. Gratifyingly, when **17a** was submitted to the conditions established by the model substrate **9** (G2, 10 mol %, C₆D₆, 0.02 M, 65 °C, 1 h, entry 5, Table 1), the desired product **18a** was efficiently generated as the major product (Table 2, entry 1).¹⁶ A plausible mechanism for the desired EYRCM pathway is shown in Scheme 4 (Path A). A minor amount (6%) of the uncyclized triene product **19a** was also observed as a result of an intermolecular cross-metathesis out competing the desired intramolecular ring closing metathesis at the C4–C5 olefin (Scheme 4, Path B). The formation of the intermolecular cross-metathesis product **19a** was greatly favored by increasing both the concentration from 0.02 M to 0.06 M and temperature from 65 °C to 80 °C in addition to reducing the catalyst loading to 5 mol % (Table 2, entry 2). Interestingly, 8% of the minor cyclopentenyl product **20a** was also observed under these conditions. It is plausible that the formation of this product corresponds to the




Scheme 2. Synthesis of the aldehyde **8**.



Scheme 3. Use of aldehyde **8** for synthesis of various dienynes.

Table 2
The EYRCM with the allylsilane tether^a




Scheme 5. Synthesis of the allyloxysilane tether substrates.

Entry	Substrate	Cat	Conditions	Results (%)				
				17	16	18	19	20
1	17a	G2	C ₆ D ₆ , 65 °C	—	—	94	6	—
2 ^b	17a	G2	C ₆ D ₆ , 80 °C	—	—	—	92	8
3	17b	G1	C ₆ D ₆ , 65 °C	75	—	—	—	25
4	17b	G1	CD ₂ Cl ₂ , 40 °C	10	—	40	—	50
5	17b	G2	CD ₂ Cl ₂ , 40 °C	55	—	40	—	5
6	17b	G2	C ₆ D ₆ , 65 °C	10	—	90	—	—
7 ^c	17c	G2	C ₆ D ₆ , 80 °C	46	54	—	—	—

^a All experiments were conducted in NMR tubes under an atmosphere of argon, and product distribution was measured by direct integration of characteristic resonances for products. All experiments were stopped after 1 h unless otherwise noted.

^b G2 (5 mol %), 0.06 M concentration.

^c Reaction time 32 h.




Scheme 4. Plausible mechanisms for the EYRCM reaction.

metathesis occurring first at the sterically congested C4–C5 gem-disubstituted olefin followed by enyne metathesis (Scheme 4, Path C).¹⁷ The structure of cyclopentenyl product **20** was secured through X-ray analysis of a related derivative (vide infra).

We also explored the EYRCM reaction with substrate **17b** containing the trisubstituted olefin. Unexpectedly, when **17b** was submitted to **G1** in C₆D₆ at 65 °C (Table 2, entry 3), the five-membered ring substrate **20b** was the only observable product. By changing the solvent to CD₂Cl₂ and lowering the temperature to 40 °C, both the desired product **18b** and the undesired cyclopentene product **20b** were afforded in a 4:5 ratio (Table 2, entry 4). Significantly, the EYRCM conditions employing **G2** in C₆D₆ at 65 °C for 1 h generated the desired product **18b** exclusively (Table 2, entry 6). Interestingly, when the tetraenyne **17c** was exposed to the EYRCM reaction conditions (**G2**, 10 mol %, C₆D₆, 0.02 M, 80 °C, 32 h), none of the desired product **18c** was generated (Table 2, entry 7). Instead, over prolonged reaction times, desilylation occurred to generate **16c**, indicating that conjugation of the alkyne may significantly deactivate the substrate toward EYRCM.

Given the complications with oxidative desilylation of allylic silanes **18**,⁶ we also explored the corresponding dialkylallyloxysil-

Table 3
The EYRCM with the allyloxysilane tether



Entry	Substrate	Conditions	Results (%)			
			27	28	5	29
1	27a	C ₆ D ₆ , 65 °C	33 ^a	66 ^a	—	—
2	27a	PhMe-d ₈ , 110 °C	—	99 ^a	—	—
3	27a	PhMe, 110 °C, TBAF	—	—	48 ^b	—
4	27d	PhMe, 110 °C, TBAF	—	—	64 ^b	17 ^b

^a Experiments were conducted in NMR tubes under an atmosphere of argon and product distribution was measured by direct integration of characteristic resonances for products.

^b Isolated yields.

anes. Gratifyingly, the diethylallyloxysilane tethered substrates **27a** and **27d** were efficiently prepared through selective silylation of the secondary alcohol (Scheme 5).¹⁸ ¹H NMR studies on the diethylallyloxysilyl substrate **27a** indicated that the EYRCM reaction to form the 7,6-bicycle **28a** (Table 3, entry 1) required higher reaction temperatures than those observed with the allylsilane tether (vide supra, entry 1, Table 2). The desired product **28a** was cleanly generated when subjected to the EYRCM reaction in toluene-*d*₈ at 110 °C (Table 3, entry 2). The heptacyclic silyloxy ring system **28** was very sensitive to isolation, hence we sought a tandem EYRCM-desilylation sequence. Using this method, we were able to directly isolate the corresponding triols **5a** and **5d** in 48% and 64% yields, respectively (Table 3, entries 3 and 4). Notably, the versatile product **5d** contains a *p*-methoxybenzyl (PMB) group poised for further elaboration toward the synthesis of various functional bicyclic illudin derivatives. Interestingly, when **27d** was subjected to this optimal EYRCM-TBAF condition we also isolated the diol **29d** in 17% yield (Table 3, entry 4). The formation of this product is consistent with the EYRCM pathway involving initial enyne metathesis at the C4–C5 olefin (vide supra, Scheme 4, Path C). The structure of **29d** was secured through X-ray crystallographic analysis of the corresponding bis-*p*-nitrobenzoate derivative.¹⁹

In summary, the subtle factors influencing the competing pathways in a critical EYRCM reaction were discussed. Our convergent approach to the bicyclic warhead of illudins involves the union of a readily accessible key aldehyde **8** with various lithium acetylides and optimal silicon-based olefin tethers to enable access to an array of dienyne **7**. A versatile EYRCM cascade reaction rapidly constructs the cyclohexenyl B-ring common to the illudins. Subtle changes in the EYRCM conditions greatly affect the outcome of the metathesis reaction, which can proceed through three different pathways to generate products **18**, **19**, and **20** (Scheme 4, Paths A–

C). This strategy provides ready access to the synthesis of various functionalized precursors to the core warheads of the illudin anti-tumor natural products. The evaluation of these fused bicycles in the synthesis of illudin derivatives and their respective biological evaluation will be reported in due course.

Acknowledgments

M.M. is an Alfred P. Sloan Research Fellow, a Beckman Young Investigator, and a Camille Dreyfus Teacher-Scholar. We thank Justin Kim and Dr. Peter Müller for assistance with X-ray crystallographic analysis. We acknowledge financial support in part by NIH-NIGMS (GM074825) and Amgen.

References and notes

- (a) Anchel, M.; Hervey, A.; Robbins, W. J. *Proc. Natl. Acad. Sci. U.S.A.* **1952**, *38*, 927; (b) McMorris, T. C.; Anchel, M. J. *Am. Chem. Soc.* **1965**, *87*, 1594.
- (a) Kelner, M. J.; McMorris, T. C.; Taetle, R. J. *Natl. Cancer Inst.* **1990**, *82*, 1562; (b) McMorris, T. C.; Kelner, M. J.; Chadha, R. K.; Siegel, J. S.; Moon, S.; Moya, M. M. *Tetrahedron* **1989**, *45*, 5433; (c) Gong, J.; Vaidyanathan, V. G.; Yu, X.; Kensler, T. W.; Peterson, L. A.; Sturla, S. J. *J. Am. Chem. Soc.* **2007**, *129*, 2101; (d) Neels, J. F.; Gong, J.; Yu, X.; Sturla, S. J. *Chem. Res. Toxicol.* **2007**, *20*, 1513.
- McMorris, T. C.; Kelner, M. J.; Wang, W.; Yu, J.; Estes, L. A.; Taetle, R. J. *Nat. Prod.* **1996**, *59*, 896.
- (a) Alexandre, J.; Raymond, E.; Kaci, M. O.; Brian, E. C.; Lokiec, F.; Kahatt, C.; Faivre, S.; Yovine, A.; Goldwasser, F.; Smith, S. L.; MacDonald, J. R.; Misset, J.-L.; Cvitkovic, E. *Clin. Cancer Res.* **2004**, *10*, 3377; (b) Yeo, W.; Boyer, M.; Chung, H. C.; Ong, S. Y. K.; Lim, R.; Zee, B.; Ma, B.; Lam, K. C.; Mo, F. K. F.; Ng, E. K. W.; Ho, R.; Clarke, S.; Roh, J. K.; Beale, P.; Rha, S. Y.; Jeung, H. C.; Soo, R.; Goh, B. C.; Chan, A. T. C. *Cancer Chemother. Pharmacol.* **2007**, *59*, 295; (c) Wiltshire, T.; Senft, J.; Wang, Y.; Konat, G. W.; Wenger, S. L.; Reed, E.; Wang, W. *Mol. Pharmacol.* **2007**, *71*, 1051; (d) Kelner, M. J.; McMorris, T. C.; Rojas, R. J.; Estes, L. A.; Suthipinijtham, P. *Cancer Chemother. Pharmacol.* **2008**, *63*, 19; (e) Dings, R. P. M.; Van Laar, E. S.; Webber, J.; Zhang, Y.; Griffin, R. J.; Waters, S. J.; MacDonald, J. R.; Mayo, K. H. *Cancer Lett.* **2008**, *265*, 270.
- For total syntheses of illudin M and S, see: (a) Matsumoto, T.; Shirahama, H.; Ichihara, A.; Shin, H.; Kagawa, S.; Sakan, F.; Matsumoto, S.; Nishida, S. *J. Am. Chem. Soc.* **1968**, *90*, 3280; (b) Matsumoto, T.; Shirahama, H.; Ichihara, A.; Shin, H.; Kagawa, S.; Sakan, F.; Miyano, K. *Tetrahedron Lett.* **1971**, 2049; (c) Kinder, F. R.; Bair, K. W. *J. Org. Chem.* **1994**, *59*, 6965; For total syntheses of Acylfulvene and Irofulven, see: (d) McMorris, T. C.; Hu, Y.; Yu, J.; Kelner, M. *Chem. Commun.* **1997**, 315; (e) Brummond, K. M.; Lu, J.; Petersen, J. *J. Am. Chem. Soc.* **2000**, *122*, 4915; (f) McMorris, T. C.; Staake, M. D.; Kelner, M. *J. Org. Chem.* **2004**, *69*, 619; (g) Gong, J.; Neels, J. F.; Yu, X.; Kensler, T. W.; Peterson, L. A.; Sturla, S. J. *J. Med. Chem.* **2006**, *49*, 2593.
- Movassaghi, M.; Piizzi, G.; Siegel, D. S.; Piersanti, G. *Angew. Chem., Int. Ed.* **2006**, *45*, 5859.
- For representative examples, see: (a) Kim, S.-H.; Bowden, N.; Grubbs, R. H. *J. Am. Chem. Soc.* **1994**, *116*, 10801; (b) Zuercher, W. J.; Scholl, M.; Grubbs, R. H. *J. Org. Chem.* **1998**, *63*, 4291; (c) Layton, M. E.; Morales, C. A.; Shair, M. D. *J. Am. Chem. Soc.* **2002**, *124*, 773; (d) Fukumoto, H.; Takanishi, K.; Ishihara, J.; Hatakeyama, S. *Angew. Chem., Int. Ed.* **2006**, *45*, 2731; For a review, see: (e) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. *Angew. Chem., Int. Ed.* **2005**, *44*, 4490.
- (a) Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. *J. Am. Chem. Soc.* **1996**, *118*, 9606; (b) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. *Org. Lett.* **1999**, *1*, 953.
- The allylcarbonate fragmentation may involve a competing pathway in which catalyst decomposition products may form π -allyl complexes. For an example of ruthenium π -allyl complex formation with allylcarbonates, see: Gürbüz, N.; Özdemir, I.; Çetinkaya, B.; Renaud, J.-L.; Demerseman, B.; Bruneau, C. *Tetrahedron Lett.* **2006**, *47*, 535.
- For representative examples of allyldialkylsilicon tether mediated olefin metathesis, see: (a) Chang, S.; Grubbs, R. H. *Tetrahedron Lett.* **1997**, *38*, 4757; (b) Yao, Q. *Org. Lett.* **2001**, *3*, 2069.
- For examples of metathesis reactions using allyloxysilane tethers, see: (a) Hoye, T. R.; Promo, M. A. *Tetrahedron Lett.* **1999**, *40*, 1429; (b) Briot, A.; Bujard, M.; Gouverneur, V.; Nolan, S. P.; Mioskowski, C. *Org. Lett.* **2000**, *2*, 1517; (c) Van de Weghe, P.; Aoun, J.-G.; Boiteau, D.; Eustache, J. *Org. Lett.* **2002**, *4*, 4105; (d) Postema, M. H.; Piper, J. L. *Tetrahedron Lett.* **2002**, *43*, 7095; (e) Evans, P. E.; Cui, J.; Gharpure, S. J.; Polosukhin, A.; Zhang, H.-R. *J. Am. Chem. Soc.* **2003**, *125*, 14702.
- Zefrov, N. S.; Kuznetsova, T. S.; Kozhushkov, S. I.; Surmina, L. S.; Rashchupkina, Z. A. *Zh. Org. Khim.* **1983**, *19*, 541.
- (a) Bandini, M.; Cozzi, P. G.; Melchiorre, P.; Umami-Ronchi, A. *Tetrahedron Lett.* **2001**, *42*, 3041; (b) Bandini, M.; Cozzi, P. G.; Garelli, A.; Melchiorre, P.; Umami-Ronchi, A. *Eur. J. Org. Chem.* **2002**, 3243.
- The alkynes **15b** and **15c** were prepared according to literature procedures. **15b**: Van Boom, J. H.; Brandsma, L.; Arens, J. F. *Rec. Trav. Chim. Pays-Bas* **1966**, *85*, 952. **15c**: Apparu, M.; Barrelle, M. *Bull. Soc. Chim. Fr.* **1983**, *83*. **15d**: Treatment of corresponding propargyl alcohol with PMBCl.
- For clarity only the major diastereomer is shown.
- On larger scale, **18a** could be isolated in 76% yield using optimized EYRCM conditions.
- It may also be plausible that the formation of product **20** occurs through initial complexation of the metathesis catalyst with the alkyne followed by EYRCM.
- Diethylallyloxysilylchloride was prepared according to: Krolevets, A. A.; Antipova, V. V.; Popov, A. G.; Adamov, A. V. *Zh. Obsch. Khim.* **1988**, *58*, 2274.
- The crystal structure of the corresponding *bis-p*-nitrobenzoate derivative of **29d** has been deposited at the Cambridge Crystallographic Data Center, please see: CCDC# 735275.